Pasithea Therapeutics
KTTA
12 hedge funds and large institutions have $122K invested in Pasithea Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.02% less ownership
Funds ownership: 0.07% → 0.05% (-0.02%)
34% less capital invested
Capital invested by funds: $184K → $122K (-$62.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$5.87K |
| 4 |
NGA
Naples Global Advisors
Naples,
Florida
|
+$5.81K |
| 5 |
MSFP
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
|
+$1.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$59.3K |
| 2 |
HF
HRT Financial
New York
|
-$20K |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.6K |
| 4 |
Jane Street
New York
|
-$7.28K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.74K |
KTTA Hedge Fund Activity: Q3 2023 in Review
12 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2023, worth a combined $122K — down 34% from $184K a quarter earlier.
Fund positioning in KTTA was balanced in Q3 2023: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $21.1K. The largest seller was Vanguard Group, exiting entirely with an estimated $59.3K sold.
- 12 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $122K of Pasithea Therapeutics stock for Q3 2023, down 34% quarter-over-quarter.
- 4 funds opened new Pasithea Therapeutics positions in Q3 2023 and 4 closed out, a net change of 0 holders.
- The largest Pasithea Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $21.1K added.
- The largest Pasithea Therapeutics seller in Q3 2023 was Vanguard Group, an estimated $59.3K sold.
Based on aggregated 13F filings for Q3 2023.